Epidemiology and Management of Hepatocellular Carcinoma
Laura Kulik,Hashem B. El-Serag +1 more
Reads0
Chats0
TLDR
The major risk factors for hepatocellular carcinoma (HCC) in contemporary clinical practice are becoming increasingly related to sustained virological response after hepatitis C, suppressed hepatitis B virus during treatment, and alcoholic and nonalcoholic fatty liver disease.About:
This article is published in Gastroenterology.The article was published on 2019-01-01 and is currently open access. It has received 958 citations till now. The article focuses on the topics: Hepatitis C & Hepatocellular carcinoma.read more
Citations
More filters
Journal ArticleDOI
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.
TL;DR: This work assessed the global incidence, mortality, and disability‐adjusted life‐years (DALYs) related to chronic liver disease (primary liver cancer [LC] and cirrhosis] related to Chronic hepatitis B virus, hepatitis C virus, and nonalcoholic fatty liver disease.
Journal ArticleDOI
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet,Josep M. Llovet,Thierry de Baere,Thierry de Baere,Laura Kulik,Philipp K. Haber,Tim F. Greten,Tim Meyer,Tim Meyer,Riccardo Lencioni +9 more
TL;DR: In this paper, the authors analyse data from randomized and uncontrolled studies reported with ablative and locoregional techniques and examine the expected effects of combinations with systemic treatments, and discuss trial design and benchmarks to be used as a reference for future investigations in a promising new era for HCC treatment.
Journal ArticleDOI
Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature
Ivana Milosevic,Ankica Vujovic,Aleksandra Barac,Marina Djelic,Milos Korac,Aleksandra Radovanovic Spurnic,Aleksandra Radovanovic Spurnic,Ivana Gmizic,Olja Stevanovic,Vladimir Djordjevic,Nebojsa Lekic,Edda Russo,Amedeo Amedei,Amedeo Amedei +13 more
TL;DR: It is concluded that population-level shifts in GM could play a regulatory role in the gut-liver axis and, consequently, etiopathogenesis of chronic liver diseases.
Book ChapterDOI
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.
TL;DR: This review examines the results of efforts in classifying HCC at the molecular, metabolic and immunologic levels and the ways they can be leveraged to develop targeted treatment options for HCC.
Journal ArticleDOI
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
TL;DR: An evidence-based review addressing HCC risk in patients with NAFLD is presented and Best Practice Advice statements are provided to address key issues in clinical management.
References
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo,Richard S. Finn,Shukui Qin,Kwang Hyub Han,Kenji Ikeda,Fabio Piscaglia,Ari David Baron,Joong-Won Park,Guohong Han,Jacek Jassem,Jean-Frédéric Blanc,Arndt Vogel,Dmitry Komov,T.R. Jeffry Evans,Carlos Lopez,Corina E. Dutcus,Matthew Guo,Kenichi Saito,Silvija Kraljevic,Toshiyuki Tamai,Min Ren,Ann-Lii Cheng +21 more